leadf
logo-loader
viewKintara Therapeutics
(
NASDAQ:KTRA
)

Kintara Therapeutics extends cash runway out 6 months into calendar year 2022 in 3Q financial report

Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive the biotechnology group closed its fiscal third quarter with cash and cash equivalents of about $15.7 million, which is expected to be sufficient to fund its planned operations to the second quarter of calendar year 2022.

Zarrabian says Kintara achieved the healthy cash runway primarily due to prudent cash management as well as the exercise of previously issued warrants. Zarrabian also updated investors on the group's ongoing clinical trials including its AGILE study to treat brain cancer.

Quick facts: Kintara Therapeutics

Follow
NASDAQ:KTRA

Price: 0.88 USD

Market Cap: $28.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Kintara Therapeutics enrolls patients at 26 sites within around 7 months

Kintara Therapeutics (NASDAQ:KTRA) Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites. Zarrabian...

2 weeks, 3 days ago

2 min read